Back to search

Peptide record

TPDB13361

SHIVA 10 (1-16) SHIVA 10 (1-16) Ac Antibacterial Anticancer Antifungal Toxicity standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB13361
SHIVA 10 (1-16) SHIVA 10 (1-16) Ac
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF pep-lab Antifungipept CAFPdb dbAMP
standard
No
A 23-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, ACP740 _ACP240, and other sources, with an available 3D structural model.
Sequence
KTKLFKKFAKKLAKKLKKLAKKL
Physicochemical Analysis
C133H241N35O25
RNDCEQGHIMPSWYV
K
2730.60
11.55
12
0
10
+12
6.45
-0.761
97.83
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
3
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
5
L
12
K
0
M
2
F
0
P
0
S
1
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 5 K: 12 M: 0 F: 2 P: 0 S: 0 T: 1 W: 0 Y: 0 V: 0
Chemical Descriptors
23
C133H241N35O25
2730.60
11.55
+12
6.45
-0.761
Free
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 8 records
Evidence 1 Activity

Activity

LD50
LD50 =29 µg/ml
Anticancer
29 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50
LD50 =35 µg/ml
Anticancer
35 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =76 µg/ml
Anticancer
76 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =64 µg/ml
Anticancer
64 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =28 µg/ml
Anticancer
28 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =97 µg/ml
Anticancer
97 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 7 Activity

Activity

LD50
Toxicity
28 µg/mL
Cytotoxic
LD50 | 28 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 8 Activity

Activity

50% Hemolysis
Toxicity
900 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 900 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005